| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 985 | 2021 |
| Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score B Scheiner, K Pomej, MM Kirstein, F Hucke, F Finkelmeier, O Waidmann, ... Journal of hepatology 76 (2), 353-363, 2022 | 203 | 2022 |
| Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups M Pinter, B Scheiner, M Peck-Radosavljevic Gut 70 (1), 204-214, 2021 | 201 | 2021 |
| Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease M Pons, S Augustin, B Scheiner, M Guillaume, M Rosselli, SG Rodrigues, ... Official journal of the American College of Gastroenterology| ACG 116 (4 …, 2021 | 195 | 2021 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 185 | 2022 |
| Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome S Piano, HH Schmidt, X Ariza, A Amoros, A Romano, A Hüsing-Kabar, ... Clinical Gastroenterology and Hepatology 16 (11), 1792-1800. e3, 2018 | 172 | 2018 |
| Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality D Costa, B Simbrunner, M Jachs, L Hartl, D Bauer, R Paternostro, ... Journal of Hepatology 74 (4), 819-828, 2021 | 160 | 2021 |
| Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort B Scheiner, MM Kirstein, F Hucke, F Finkelmeier, K Schulze, J von Felden, ... Alimentary pharmacology & therapeutics 49 (10), 1323-1333, 2019 | 138 | 2019 |
| Acid-base disorders in liver disease B Scheiner, G Lindner, T Reiberger, B Schneeweiss, M Trauner, C Zauner, ... Journal of hepatology 67 (5), 1062-1073, 2017 | 122 | 2017 |
| HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease G Semmler, EL Meyer, K Kozbial, P Schwabl, S Hametner-Schreil, ... Journal of hepatology 76 (4), 812-821, 2022 | 108 | 2022 |
| Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease P Schwabl, M Mandorfer, S Steiner, B Scheiner, D Chromy, M Herac, ... Alimentary pharmacology & therapeutics 45 (1), 139-149, 2017 | 104 | 2017 |
| Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease B Scheiner, G Semmler, F Maurer, P Schwabl, TA Bucsics, R Paternostro, ... Liver International 40 (1), 194-204, 2020 | 84 | 2020 |
| Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 80 | 2022 |
| Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma L Schulte, B Scheiner, T Voigtländer, S Koch, N Schweitzer, S Marhenke, ... Liver International 39 (4), 714-726, 2019 | 75 | 2019 |
| Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes M Jachs, L Hartl, D Schaufler, C Desbalmes, B Simbrunner, E Eigenbauer, ... Gut 70 (9), 1758-1767, 2021 | 74 | 2021 |
| Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma B Scheiner, M Kirstein, S Popp, F Hucke, S Bota, N Rohr-Udilova, ... Liver Cancer 8 (3), 203-217, 2019 | 69 | 2019 |
| Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience T de Castro, LS Jochheim, M Bathon, S Welland, B Scheiner, K Shmanko, ... Therapeutic Advances in Medical Oncology 14, 17588359221080298, 2022 | 67 | 2022 |
| Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis A Guerrero, L Del Campo, F Piscaglia, B Scheiner, G Han, F Violi, ... Journal of hepatology 79 (1), 69-78, 2023 | 66 | 2023 |
| Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension K Wöran, G Semmler, M Jachs, B Simbrunner, DJM Bauer, T Binter, ... Clinical Gastroenterology and Hepatology 20 (2), e251-e266, 2022 | 64 | 2022 |
| Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding N Pfisterer, C Dexheimer, EM Fuchs, T Bucsics, P Schwabl, M Mandorfer, ... Alimentary Pharmacology & Therapeutics 47 (7), 966-979, 2018 | 64 | 2018 |
